INDIANAPOLIS, June 13, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising…

Read the full release →

News provided by PR Newswire.